Macular Disease Foundation Australia logo

    Research news

    Research News

    The latest funding round now brings MDFA’s commitment to macular disease research to $7.2 million across 44 projects since 2011.

    Read more

    Most recent

    2025 Grant Family Fund Award Recipient

    Exploring exosomal therapeutics delivery strategies for macular disease

    2025 Research Grant Recipient

    Reducing the risk of end-stage complications of neovascular age-related macular degeneration (AMD): macular atrophy and subretinal fibrosis

    2025 Research Grant Recipient

    Towards a personalised approach to predicting and preventing progression of age-related macular degeneration

    2025 Research Grant Recipient 

    Genotype-phenotype correlations in PRPH2-associated retinal dystrophy

    2025 Research Grant Recipient  

    Nocturnal hypoxia: An unrecognised risk factor for neovascular age-related macular degeneration

    2025 Grant Family Fund Award Recipient

    Macular vascular disease: software standardisation and data harmonisation to accelerate the development of new imaging biomarkers and therapies

    2025 Grant Family Fund Award Recipient

    Next-generation gene therapy for Stargardt Disease: Enhanced AAV-mediated ABCA4 delivery to restore vision

    $1 million investment in new macular disease research 

    MDFA is Australia’s largest source of research funding in the field of macular disease outside of government.

    MDFA invests $1 million into macular disease research

    Macular Disease Foundation Australia today announced it has awarded more than $1 million to eight

    Loading...